ReviewInternational journal of molecular sciences2022
Exploring the Links between Obesity and Psoriasis: A Comprehensive Review.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Transcriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity.Genes and immunity · 2024Pooled it
- A genome-wide cross-trait analysis identifies shared loci and causal relationships of obesity and lipidemic traits with psoriasis.Frontiers in immunology · 2024Pooled it
- Predictors of Efficacy Maintenance After Vunakizumab Discontinuation in Patients With Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of a Randomized Controlled Trial.International journal of dermatology · 2026Trial
- Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis.JCI insight · 2026Trial
- Rewiring the psoriasis-metabolism axis: therapeutic potential of saroglitazar beyond PPAR modulation.Inflammopharmacology · 2026Review
- Genetic modification of obesity-associated disability progression in multiple sclerosis.Journal of neurology · 2026Article
- Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care.RMD open · 2026Review
- Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review.BMC cardiovascular disorders · 2026Review
- Review
- The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.Nature reviews. Rheumatology · 2026Review
- Aerobic Exercise Attenuates Epidermal Hyperplasia in an Obesity-Associated Psoriasiform Dermatitis Model.International journal of molecular sciences · 2026Article
- Review
- Dual impact of smoking cessation and post-cessation weight change on psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Real-World Effectiveness of Brodalumab in Challenging Psoriasis Subgroups: Insights from the PSO-TARGET Cohort.Dermatology and therapy · 2026Article
- Effectiveness of Biological Therapy in Psoriasis: Real-World Evaluation of SII and SIRI as Biomarkers of Systemic Inflammation.Dermatology practical & conceptual · 2026Article
- Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.Communications medicine · 2026Article
- The Potential Link and Role of Zyxin in the Pathogenesis of Psoriasis and Its Associated Comorbidities.International journal of molecular sciences · 2026Article
- Article
- Sex hormone-psoriasis interactions: from sex-specific clinical features to immunoregulatory mechanisms.Frontiers in immunology · 2026Review
- Association of BRI With Psoriasis and Mediator Effect of SII: A Study Based on NHANES (2003-2006, 2009-2014).Mediators of inflammation · 2026Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major public health issue worldwide since it is associated with the development of chronic comorbidities such as type 2 diabetes, dyslipidemias, atherosclerosis, some cancer forms and skin diseases, including psoriasis. Scientific evidence has indicated that the possible link between obesity and psoriasis may be multifactorial, highlighting dietary habits, lifestyle, certain genetic factors and the microbiome as leading factors in the progress of both pathologies because they are associated with a chronic pro-inflammatory state. Thus, inflammation management in obesity is a plausible target for psoriasis, not only because of the sick adipose tissue secretome profile but also due to the relationship of obesity with the rest of the immune derangements associated with psoriasis initiation and maintenance. Hence, this review will provide a general and molecular overview of the relationship between both pathologies and present recent therapeutic advances in treating this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.